Package Leaflet: Information for the User
Lamisil 10 mg/g cutaneous spray solution
terbinafine hydrochloride
Read the package leaflet carefully before starting to use this medication, as it contains important information for you.
Contents of the package leaflet:
Lamisil is an antifungal medication for use on the skin. It works by preventing the growth of fungi that cause skin problems.
Lamisil is used to treat:
Do not use Lamisil:
Tell your doctor or pharmacist if this is the case and do not use this medication.
Warnings and precautions
Consult your doctor or pharmacist before starting to use Lamisil.
Other medications and Lamisil
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication. Lamisil should not be used during pregnancy unless strictly necessary.
Do not use Lamisil while breastfeeding.
Children who are breastfed should be kept away from any treated skin area, including the breast.
Using this medication does not affect your ability to drive or use machines.
Important information about some of the ingredients of Lamisil cutaneous spray solution
This medication contains 48.54 mg of propylene glycol in each milliliter of cutaneous spray solution. It also contains 6.83 g of alcohol (ethanol) in each package, which is equivalent to 227.8 mg/ml. It may cause a burning sensation on damaged skin.
Follow the administration instructions for this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
Apply the cutaneous spray solution to the affected area once or twice a day, as indicated below, unless your doctor tells you otherwise.
Instructions for use
Follow these instructions carefully:
If after one week of treatment with Lamisil there are no signs of improvement, consult your doctor or pharmacist.
Discard any remaining solution12 weeks after first opening.
To help the treatment
Keep the affected skin area clean, washing it regularly. Dry it carefully with gentle patting and without rubbing. Try not to scratch the area, even if you feel itching, as this may harm you and slow down the healing process or spread the infection.
Since these infections can be easily transmitted to others, remember to use your own towel and clothes and not share them with anyone. To protect yourself from reinfection, wash your clothes and towels frequently.
If you use more Lamisil than you should
If you have accidentally ingested some of the product, inform your doctor immediately, who will tell you what to do.
In case of overdose or accidental ingestion, consult the Toxicology Information Service. Phone 91 562 04 20.
If you forget to use Lamisil
If you forget to apply the cutaneous spray solution, apply it as soon as you remember, and then continue with the next dose at the usual time. If you remember at the time of the next application, just apply the normal amount and continue with the usual schedule.
Do not apply a double dose to make up for forgotten doses.
Use the cutaneous spray solution as indicated. This is important, as the infection may recur if you forget several applications.
If you stop using Lamisil
Apply this medication until you complete the recommended treatment period, even if the infection seems to improve after a few days. The infection may recur if you stop the treatment too early.
If you have any further questions about using this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
STOP using Lamisil and seek medical help immediatelyif you experience any of the following symptoms, which may be signs of an allergic reaction:
Some side effects are common(may affect up to 1 in 10 patients)
skin peeling, itching.
Some side effects are uncommon(may affect up to 1 in 100 patients)
skin injury, crust formation, skin disorder, changes in skin color, skin redness (erythema), burning, pain, pain at the application site, irritation at the application site.
Some side effects are rare(may affect up to 1 in 1,000 patients)
skin dryness, rash and itching (contact dermatitis), redness and burning (eczema).
eye irritation.
worsening of skin condition.
Other side effects reported(frequency not known)
allergic reaction (hypersensitivity)
rash
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet.
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use (www.notificaRAM.es). By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the package after CAD. The expiration date is the last day of the month indicated.
Do not store above 30°C. Do not refrigerate.
Replace the cap on the bottle after use. Discard any remaining solution 12 weeks after first opening.
Medications should not be disposed of through wastewater or household waste. Deposit the packages and medications you no longer need at the SIGRE collection point in your pharmacy. If you have any questions, ask your pharmacist how to dispose of packages and medications you no longer need. This will help protect the environment.
Composition of Lamisil 10 mg/g cutaneous spray solution
Appearance of the product and package contents
Lamisil cutaneous spray solution is a clear, colorless to slightly yellowish liquid. It is available in 30 ml bottles.
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 – Barcelona
Spain
Manufacturer
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 – Barcelona
Spain
Novartis Pharma GmbH
Roonstrasse 25
90429 Nürnberg
Germany
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Date of the last revision of this package leaflet:March 2022
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of LAMISIL 10 mg/g CUTANEOUS SPRAY SOLUTION in October, 2025 is around 5.28 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.